Trials / Completed
CompletedNCT00620685
A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
A 4-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Pharmacokinetic Profile Of 1 And 5 Mg Ph-797804 Administered Once Daily In Subjects With Rheumatoid Arthritis Who Are Taking Oral Methotrexate
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Tablet, once daily for 4 weeks |
| DRUG | PH-797804 | Tablet, 1 mg PH-797804, once daily for 4 weeks |
| DRUG | PH-797804 | Tablet, 5 mg PH-797804, once daily for 4 weeks |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-02-21
- Last updated
- 2018-11-08
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00620685. Inclusion in this directory is not an endorsement.